Sanofi/Re­gen­eron win a new tri­al on Pralu­ent patents; Bridge­Bio bankrolls $30M biotech start­up

→  Af­ter com­ing per­ilous­ly close to see­ing their PC­SK9 drug Pralu­ent jerked off the mar­ket, Sanofi and Re­gen­eron have won a new tri­al in the case in­volv­ing a ri­val drug at Am­gen. An ap­peals court is giv­ing their at­tor­neys a green light to raise is­sues re­gard­ing the va­lid­i­ty of the patents.

→ Bridge­Bio is bankrolling a biotech start­up to the tune of $30 mil­lion. Part­ner­ing with MD An­der­son, the start­up — dubbed Navire Phar­ma — will fund work on in­hibit­ing SHP2 in fight­ing can­cer tu­mors. Shafique Vi­rani, a busi­ness de­vel­op­ment ex­ec at Roche/Genen­tech, has been named the new CEO. “Navire’s com­pounds po­tent­ly bind SHP2 and pre­vent ac­ti­va­tion of the pro­tein, block­ing its abil­i­ty to pro­mote tu­mor growth,” said Vi­rani.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.